Effective treatment of autoimmune hepatitis-primary biliary cholangitis overlap syndrome with obeticholic acid

Rev Esp Enferm Dig. 2020 Sep;112(9):737. doi: 10.17235/reed.2020.6883/2020.

Abstract

There is no consensus treatment for patients with autoimmune hepatitis (AIH) - primary biliary cholangitis (PBC) overlap syndrome who are not responding to conventional therapy. We present a case of a 43-yr-old woman with AIH-PBC overlap syndrome treated with obeticholic acid (OCA). The patient showed a reduction in liver enzymes and no fibrosis progression during 15 months of follow up.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Chenodeoxycholic Acid / analogs & derivatives
  • Chenodeoxycholic Acid / therapeutic use
  • Female
  • Hepatitis, Autoimmune* / complications
  • Hepatitis, Autoimmune* / drug therapy
  • Humans
  • Liver Cirrhosis, Biliary* / complications
  • Liver Cirrhosis, Biliary* / drug therapy
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • obeticholic acid
  • Chenodeoxycholic Acid
  • Ursodeoxycholic Acid